39 Erectile Dysfunction Clinical Trials in Aurora, IL (2026)

Q: How do I join a clinical trial in Aurora?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you.

Recruiting Erectile Dysfunction Studies in Aurora

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Aurora, ILPHASE33,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT00670735Recruiting

HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)

The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydroc...

Aurora, IL1,400 participantsUniversity of Utah

View Study Details

NCT05768139Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

Aurora, ILPHASE1880 participantsEli Lilly and Company

View Study Details

NCT06073431Recruiting

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be r...

Aurora, IL800 participantsUniversity of Rochester

View Study Details

NCT06380751Recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positiv...

Aurora, ILPHASE3788 participantsAstraZeneca

View Study Details

NCT04629014Recruiting

Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure

This study proposes to quantify and describe the quality of life of children with intestinal failure, and to identify the medical and socio-economic factors that impact this quality of life, using dat...

Aurora, IL750 participantsBoston Children's Hospital

View Study Details

NCT06112314Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

Aurora, ILPHASE3680 participantsImmunocore Ltd

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Aurora, ILPHASE1572 participantsArriVent BioPharma, Inc.

View Study Details

NCT05946278Recruiting

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

Osteoporosis is an age related disease in which a person's bone slowly becomes weaker with time. The bones may become so weak that they break easily such as a fall from standing height. The most commo...

Aurora, IL550 participantsUniversity of Colorado, Denver

View Study Details

NCT06384352Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evalu...

Aurora, ILPHASE1500 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT03093116Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

Aurora, ILPHASE1500 participantsTurning Point Therapeutics, Inc.

View Study Details

NCT05267821Recruiting

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

Aurora, ILPHASE2500 participantsNationwide Children's Hospital

View Study Details

NCT06697197Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors....

Aurora, ILPHASE1413 participantsBristol-Myers Squibb

View Study Details

NCT06264180Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage III...

Aurora, ILPHASE3400 participantsReplimune Inc.

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

Aurora, ILPHASE1383 participantsIambic Therapeutics, Inc

View Study Details

NCT02332668Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cance...

Aurora, ILPHASE1370 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06596473Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in ...

Aurora, ILPHASE1310 participantsBeOne Medicines

View Study Details

NCT06233942Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and ...

Aurora, ILPHASE1308 participantsBeOne Medicines

View Study Details

NCT05916469Recruiting

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, he...

Aurora, IL300 participantsOregon Health and Science University

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Aurora, ILPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06997029Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer....

Aurora, ILPHASE1234 participantsBristol-Myers Squibb

View Study Details

NCT05398484Recruiting

Psilocybin Therapy in Advanced Cancer

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existent...

Aurora, ILPHASE2200 participantsNYU Langone Health

View Study Details

NCT05902988Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers....

Aurora, ILPHASE1200 participantsVolastra Therapeutics, Inc.

View Study Details

NCT06868290Recruiting

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic P...

Aurora, ILPHASE2126 participantsNovartis Pharmaceuticals

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

Aurora, ILPHASE1120 participantsSystImmune Inc.

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

Aurora, IL100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT07220811Recruiting

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generat...

Aurora, ILPHASE2100 participantsRAPT Therapeutics, Inc.

View Study Details

NCT07282587Recruiting

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG)....

Aurora, ILPHASE290 participantsJazz Pharmaceuticals

View Study Details

NCT06799065Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and pr...

Aurora, ILPHASE190 participantsAccent Therapeutics

View Study Details

NCT05327010Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

Aurora, ILPHASE288 participantsNational Cancer Institute (NCI)

View Study Details

NCT05135975Recruiting

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, a...

Aurora, ILPHASE286 participantsNationwide Children's Hospital

View Study Details

NCT06040268Recruiting

Advair HFA in Healthy and HAPE Predisposed Subjects

The current protocol is composed of two studies. The first study is designed to carefully evaluate the safety of high-dose salmeterol/fluticasone (Advair HFA) versus placebo (hydrofluoroalkane, HFA) a...

Aurora, ILPHASE160 participantsUniversity of Colorado, Denver

View Study Details

NCT04963751Recruiting

ERAS in Pediatric & Adolescent Gynecology Preoperative Counseling

The Investigator propose a randomized trial that will assess whether participant involvement in pre-operative counseling for ERAS improves post-surgical pain scores. The Investigator will also assess ...

Aurora, ILNA60 participantsUniversity of Colorado, Denver

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Aurora, ILPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT06900595Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and...

Aurora, ILPHASE248 participantsNational Cancer Institute (NCI)

View Study Details

NCT07584226Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, a...

Aurora, ILPHASE135 participantsRelay Therapeutics, Inc.

View Study Details

NCT05711615Recruiting

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first ...

Aurora, ILPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT06376162Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or...

Aurora, ILPHASE120 participantsPedAL BCU, LLC

View Study Details

NCT07579429Recruiting

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicoti...

Aurora, ILPHASE210 participantsUniversity of Colorado, Denver

View Study Details

About Erectile Dysfunction Clinical Trials in Aurora

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 39 erectile dysfunction clinical trials recruiting participants in Aurora, IL. These studies are seeking a combined 15,942 participants. Research is being sponsored by Merck Sharp & Dohme LLC, University of Utah, Eli Lilly and Company and 27 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Aurora — FAQ

Are there erectile dysfunction clinical trials in Aurora?

Yes, there are 39 erectile dysfunction clinical trials currently recruiting in Aurora, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 39 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated August 29, 2026 from ClinicalTrials.gov